Grifols Therapeutics
Grifols Therapeutics is a global leader in plasma-derived medicines and biopharmaceutical solutions, serving patients with rare and chronic diseases through innovative healthcare products and services.
Grifols Therapeutics is a global leader in plasma-derived medicines and biopharmaceutical solutions, serving patients with rare and chronic diseases through innovative healthcare products and services.
Import Shipments
Distribution Centers
Annual Revenue
Founded
Grifols Therapeutics has recently focused on expanding plasma collection capacity, advancing research in recombinant therapies, and enhancing global supply chain resilience in response to increased demand for plasma-derived medicines.
Expansion of plasma fractionation facilities to increase production capacity
Strategic efforts to expand market presence and reach new customer segments.
Implementation of advanced technologies to improve service delivery and customer experience.
Grifols Therapeutics develops, produces, and distributes plasma-derived medicines and biopharmaceutical products that address chronic, rare, and life-threatening conditions. The company operates one of the world’s largest plasma collection networks and maintains advanced manufacturing and research facilities across multiple continents. Its portfolio includes immunoglobulins, albumin, clotting factors, and diagnostic solutions for hospitals and laboratories. Grifols Therapeutics is committed to continuous innovation, quality, and ethical leadership in the healthcare sector.
Clayton, North Carolina, USA
1909
GRF
